This article is more than 5 years old. Information may no longer be current.

Mylan releases generic FazaClo orally disintegrating tablets

Mylan recently announced the launch of clozapine orally disintegrating tablets, the generic version of Jazz Pharmaceuticals’ FazaClo, according to a company press release.

Mylan received final FDA-approval for its Abbreviated New Drug Application for 25-mg and 100-mg clozapine tablets, which are indicated for patients with schizophrenia who fail to respond to standard antipsychotic treatment.

As of Sept. 30, 25-mg and 100-mg doses of clozapine orally disintegrating tablets had U.S. sales of approximately $51.1 million for the past 12 months, according to IMS Health.

Further, IMS Health reported that Mylan currently has 272 Abbreviated New Drug Applications pending FDA approval, representing $101.8 billion in annual brand sales.